Beacon Pharmaceuticals PLC (DSE: BEACONPHAR)

Market Cap	31.53B
Revenue (ttm)	11.18B
Net Income (ttm)	512.09M
Shares Out	231.00M
EPS (ttm)	2.22
PE Ratio	61.57
Forward PE	n/a
Dividend	2.00 (1.47%)
Ex-Dividend Date	Oct 28, 2024

Volume	434,791
Open	129.80
Previous Close	129.80
Day's Range	128.40 - 138.20
52-Week Range	104.80 - 288.90
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Dec 15, 2024

About Beacon Pharmaceuticals

Beacon Pharmaceuticals PLC engages in the producing and promoting of pharmaceuticals finished formulations, lifesaving intravenous fluids, active pharmaceutical ingredients, bio-tech products, and genetic engineering products in Bangladesh and internationally. The company offers general, oncology, biotech, and chronic care products. It also provides products in various therapeutic categories that include oncology, hematology, hepatology, nephrology, antibiotics, analgesics, anti-diabetics, respiratory, cardiovascular, dermatology, gastrointesti...

• Industry: Pharmaceutical Preparations
• Founded: 2001
• Employees: 3,872
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: BEACONPHAR

Financial Performance

In 2024, Beacon Pharmaceuticals's revenue was 10.70 billion, an increase of 25.76% compared to the previous year's 8.51 billion. Earnings were 521.01 million, an increase of 2.19%.